Arena Pharmaceuticals Inc. (ARNA)

43.58
0.16 0.37
NASDAQ : Health Technology
Prev Close 43.74
Open 43.77
Day Low/High 43.40 / 44.50
52 Wk Low/High 30.00 / 50.05
Volume 391.02K
Avg Volume 588.40K
Exchange NASDAQ
Shares Outstanding 49.41M
Market Cap 2.07B
EPS -2.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Arena Pharmaceuticals Appoints Experienced Life Sciences Industry Finance Executive Manmeet S. Soni To Board Of Directors

Arena Pharmaceuticals Appoints Experienced Life Sciences Industry Finance Executive Manmeet S. Soni To Board Of Directors

SAN DIEGO, Dec. 17, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals Expands Senior Management Team To Support Commercialization And Medical Affairs

Arena Pharmaceuticals Expands Senior Management Team To Support Commercialization And Medical Affairs

SAN DIEGO, Nov. 26, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals To Participate In Upcoming Investor Conferences

Arena Pharmaceuticals To Participate In Upcoming Investor Conferences

SAN DIEGO, Calif., Nov.

Putting the Markets in Focus: Cramer's 'Mad Money' Recap (Thursday 11/15/18)

Putting the Markets in Focus: Cramer's 'Mad Money' Recap (Thursday 11/15/18)

Jim Cramer says perception is determining how stocks trade right now -- and there's a lot of negativity.

BP, Arconic, Fiat Chrysler: 'Mad Money' Lightning Round

BP, Arconic, Fiat Chrysler: 'Mad Money' Lightning Round

Jim Cramer take a closer look at BP, Arconic, Fiat Chrysler, Qualcomm, Thermo Fisher, GameStop, Arena Pharmaceuticals and more.

Arena Pharmaceuticals And United Therapeutics Announce Global License Agreement For Ralinepag

Arena Pharmaceuticals And United Therapeutics Announce Global License Agreement For Ralinepag

- Arena will receive $800M upfront, and is eligible to receive low double-digit tiered royalties, plus up to $400M in milestone payments

Arena Pharmaceuticals Provides Corporate Update And Reports Third Quarter 2018 Financial Results

Arena Pharmaceuticals Provides Corporate Update And Reports Third Quarter 2018 Financial Results

- Ralinepag open-label extension data demonstrated durable, long-term improvements in both PVR and 6MWD

Arena Pharmaceuticals: Don't Fight the Tape or Jim Cramer's Evaluation

Arena Pharmaceuticals: Don't Fight the Tape or Jim Cramer's Evaluation

Let's see what the charts suggest for risk points.

Gridlock and Economic Slowing: Cramer's 'Mad Money' Recap (Tuesday 11/6/18)

Gridlock and Economic Slowing: Cramer's 'Mad Money' Recap (Tuesday 11/6/18)

Jim Cramer explains his post-election play book: Growth stocks may be the way to go.

Canada Goose, Celgene, BlackRock: 'Mad Money' Lightning Round

Canada Goose, Celgene, BlackRock: 'Mad Money' Lightning Round

Jim Cramer weighs in on Canada Goose, Celgene, BlackRock, Nio, Hospitality Property Trust, Activision Blizzard and more.

Arena Pharmaceuticals To Release Third Quarter 2018 Financial Results And Provide Corporate Update On November 7

Arena Pharmaceuticals To Release Third Quarter 2018 Financial Results And Provide Corporate Update On November 7

SAN DIEGO, Oct. 31, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals Reports Positive Phase 2a Results For Olorinab In Patients With Abdominal Pain Associated With Crohn's Disease

Arena Pharmaceuticals Reports Positive Phase 2a Results For Olorinab In Patients With Abdominal Pain Associated With Crohn's Disease

- Olorinab demonstrated a statistically significant improvement in abdominal pain over 8 weeks of treatment

Arena Pharmaceuticals To Host R&D Day On October 4 In New York City

Arena Pharmaceuticals To Host R&D Day On October 4 In New York City

SAN DIEGO, Sept. 21, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals To Present At Upcoming Investor Conferences

Arena Pharmaceuticals To Present At Upcoming Investor Conferences

SAN DIEGO, Sept. 20, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals Presents Preclinical Data For Olorinab At International Association For The Study Of Pain World Congress

Arena Pharmaceuticals Presents Preclinical Data For Olorinab At International Association For The Study Of Pain World Congress

SAN DIEGO, Sept. 17, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals To Present At Upcoming Investor Conferences

Arena Pharmaceuticals To Present At Upcoming Investor Conferences

SAN DIEGO, Aug. 29, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals Presented Phase 1 Clinical Data For Ralinepag In Pulmonary Arterial Hypertension At The European Society Of Cardiology

Arena Pharmaceuticals Presented Phase 1 Clinical Data For Ralinepag In Pulmonary Arterial Hypertension At The European Society Of Cardiology

SAN DIEGO, Aug. 28, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals Provides Corporate Update And Reports Second Quarter 2018 Financial Results

Arena Pharmaceuticals Provides Corporate Update And Reports Second Quarter 2018 Financial Results

- Initiated ADVANCE Phase 3 Program for Ralinepag in Pulmonary Arterial Hypertension (PAH)

Arena Pharmaceuticals To Release Second Quarter 2018 Financial Results And Provide Corporate Update On Monday, August 6

Arena Pharmaceuticals To Release Second Quarter 2018 Financial Results And Provide Corporate Update On Monday, August 6

SAN DIEGO, July 30, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Company will release its second quarter 2018 financial results and provide a corporate update on Monday, August 6, 2018, after the close of the U.

First Week Of September 21st Options Trading For Arena Pharmaceuticals (ARNA)

First Week Of September 21st Options Trading For Arena Pharmaceuticals (ARNA)

Investors in Arena Pharmaceuticals Inc saw new options begin trading this week, for the September 21st expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 86 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Biotech Sector Steps Up to Provide Some Strong Action for Traders

Biotech Sector Steps Up to Provide Some Strong Action for Traders

The S&P 500 has shown the same pattern for three consecutive days.

Will the Market Go Dead for a While?

Will the Market Go Dead for a While?

The best way to deal with it is to keep on hunting for individual stocks.

The Headlines Are Wrong -- This Is an Extremely Bullish Market

The Headlines Are Wrong -- This Is an Extremely Bullish Market

It is two totally different markets when you compare the small-cap action to the big-cap indices.

Small-Caps Are the Place to Be for Now

Small-Caps Are the Place to Be for Now

We are seeing a focus on finding smaller names that may offer interesting valuations and stories.

Market Bifurcation: Individual Stocks Are Acting Better Than the Indices

Market Bifurcation: Individual Stocks Are Acting Better Than the Indices

This underperformance is being caused by pockets of weakness in bigger-cap names.

TheStreet Quant Rating: D (Sell)